Latest news with #AnnualConferenceof
NDTV
7 days ago
- Health
- NDTV
Gautam Adani Reveals Plans To Build AI-First Affordable Healthcare Ecosystem
Mumbai: Gautam Adani on Friday revealed plans to build an AI-first, multidisciplinary healthcare ecosystem that integrates affordability, scalability, and global best practices, as he shared his vision for transforming healthcare in India. Speaking at the 5th Annual Conference of the Society for Minimally Invasive Spine Surgery - Asia Pacific (SMISS-AP) in Mumbai, he called for a complete system-wide redesign to meet the needs of the future. Mr Adani, who heads the ports-to-energy conglomerate, said three years ago, on his 60th birthday, his family pledged Rs 60,000 crore towards healthcare, education, and skill development. "We did not enter healthcare because it lacked momentum. We entered because the momentum was not enough," he said. "The pace of change was out of step with the urgency of future demands. As the landscape unfolded, one truth stood out - healthcare does not need incremental upgrades. It needs a system-wide redesign. Not an evolution but a revolution rooted in intelligence as well as empathy." Citing low back pain as a leading cause of disability in India - a crisis more widespread than diabetes or heart disease - he said: "If we are to carry the full weight of our national ambition, we must first heal the spine of our people." He urged the assembled global gathering of spine surgeons and specialists to become not only medical leaders but nation-builders. Honoured to address the brilliant minds at the Annual Conference of the Society for Minimally Invasive Spine Surgery. To the world, they are spine surgeons. To their patients, they are something far greater. They restore dignity, hope and movement. And, in doing so, hold up the… — Gautam Adani (@gautam_adani) July 11, 2025 Referring to the previously announced Adani Healthcare Temples - large, 1,000-bed integrated medical campuses to be established first in Ahmedabad and Mumbai - Mr Adani said they would be "world-class, affordable, AI-first healthcare ecosystems" and would comprise "modular, scalable infrastructure of the kind that can expand rapidly in the face of pandemics or emergencies." He added that these campuses would serve as centres of excellence for clinical care, research and academic training, guided by the Mayo Clinic's global expertise in design, medical infrastructure and innovation. "We are here to build India's healthcare for tomorrow and a system that is integrated, intelligent, inclusive and inspired," he said. The industrialist laid out a vision for a future-ready healthcare system focused on five core principles - integrated care that breaks traditional silos, modular and scalable infrastructure, technologically enabled education with a focus on robotics and AI, stronger investment in nursing and paramedical training, and human-centric insurance models that prioritise patients over paperwork. Mr Adani also called upon medical entrepreneurs to explore bold new frontiers - from AI-powered spinal diagnostics to rural surgical units and global centres for robotic spinal care. "We are investing in modular, scalable infrastructure of the kind that can expand rapidly in the face of pandemics or emergencies. We are championing the creation of large, world-class healthcare institutes that bring together innovation, patient care, and applied learning under one roof," he said. He went on to stress that academic training must evolve. "So, our focus is on fostering doctors who not only heal but also lead with skills in robotics, AI, systems thinking, and healthcare management. Their education must go beyond anatomy to include empathy, ethics, and enterprise." Drawing on his own journey from diamond trading in Mumbai to building India's largest private port in Mundra, he said, "The spine you save today may belong to the engineer who builds tomorrow's bridges, the scientist who invents the next vaccine, or the entrepreneur who powers our next billion-dollar company." India's healthcare system has made significant strides in recent years, but formidable challenges persist. Government and WHO-aligned analysis shows India currently has just 20.6 doctors, nurses and midwives per 10,000 people - far below the WHO benchmark of 44.5 per 10,000. This shortage is compounded by a stark rural-urban imbalance - around 74 per cent of doctors practice in urban areas, leaving rural communities especially underserved. These gaps are reflected in overburdened clinics, rising out-of-pocket spending and reliance on unqualified providers in remote regions. Closing these gaps-and meeting India's universal health goals-demands more than incremental updates. It requires a full-scale redesign of how care is delivered, financed, staffed and scaled across diverse geographies. With a Rs 60,000 crore family commitment already pledged towards healthcare, education and skill development, the Adani Group's entry into healthcare is part of a broader national mission. "India cannot rise if her people cannot stand. And her people cannot stand without you," Mr Adani told the assembled specialists. "Let us build the backbone of a great nation."
India Gazette
20-06-2025
- Business
- India Gazette
Himachal Pradesh Speaker invites CM to CPA India Region Zone-II annual conference in Dharamshala
Shimla (Himachal Pradesh) [India], June 20 (ANI): Speaker of the Himachal Pradesh Vidhan Sabha, Kuldeep Singh Pathania, has extended a formal invitation to Chief Minister Thakur Sukhvinder Singh Sukhu to grace the inaugural ceremony of the Annual Conference of the Commonwealth Parliamentary Association (CPA), India Region, Zone-II, being held from June 30 to 1 July at Tapovan, Dharamshala. Pathania informed that eminent delegates representing Zone-II, which includes Delhi, Haryana, Punjab, and Jammu & Kashmir, will participate in the conference. Among the attendees will be the Speaker of the Lok Sabha, Deputy Chairman of the Rajya Sabha, Speakers and Deputy Speakers of State Legislative Assemblies, Leaders of the Opposition, Chief Whips, and MLAs from Member States. In addition, Speakers from the States of Karnataka, Assam, Uttar Pradesh, Gujarat, Maharashtra and Telangana have been invited as special guests. The Speaker said that the conference aims to promote meaningful dialogue on legislative procedures, democratic governance, and regional cooperation. He emphasized that the platform will facilitate the exchange of best practices and play a vital role in strengthening parliamentary institutions across the country. Earlier on Thursday, Himachal Chief Minister Sukhvinder Singh Sukhu directed to establish the dairy cooperative societies across the state adding that six new milk plants will be set up in the state. According to an official release, Chief Minister highlighted that currently 910 panchayats, dairy cooperative societies are functional and the department should work hard to increase the number of functional societies. To boost the dairy production these societies could play a crucial role in providing employment and self employment opportunities to the youth in the dairy sector, it added. Reviewing the work progress of Dagwar Milk processing plant in Kangra district, the CM directed to constitute a committee to monitor the same and get it expedited. The Chief Minister said 'this plant was expected to be completed by June, 2026 benefitting the farmers of Kangra, Una, Hamirpur and Chamba districts.' 'The present State Government was making earnest efforts to strengthen the rural economy. We want to enhance the income of the farmers associated with the dairy sector, therefore, the State Government has raised the MSP to Rs 51 per litre for cow milk and Rs 61 per litre for buffalo milk', Sukhu added. (ANI)
Yahoo
20-05-2025
- Business
- Yahoo
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
Company's NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J., May 20, 2025--(BUSINESS WIRE)--CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world's top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop resistance mutations including the T790M gatekeeper mutation. Osimertinib, a 3rd-generation covalent TKI, is efficacious against the T790M resistance mutation and prevents its onset if administered as first line therapy. However, treatment with Osimertinib inevitably induces additional mutations, especially the C797S mutation, as well as various off-target resistance mechanisms. To date, there are no approved therapies capable of overcoming mutational or non-mutational resistance to 3rd-generation TKIs. As such, there is an urgent unmet medical need to develop next-generation EGFR inhibitors that overcome these forms of resistance. While billions of dollars have been invested over the last several years on the development of 4th-generation EGFR inhibitors that overcome tumor resistance to 3rd-generation inhibitors, due to the diversity of resistance mechanisms, these inhibitors have failed to progress beyond early-stage clinical trials. At ASCO 2025, CCM Biosciences' presentation "Novel, potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy" in the Lung Cancer – Non-small cell – Metastatic session (Abstract #: 8622, will report novel 4th-generation, orally bioavailable EGFR inhibitors (CCM-205, CCM-245 and CCM-308) that can overcome both on-target and off-target resistance in lung cancer models, significantly outperforming the aforementioned 4th-generation inhibitors in the face of resistance to 3rd-generation inhibitors, and have significant potential clinical applications. In addition to their potent activity as monotherapies, CCM-205 and CCM-245 are highly efficacious in combination with 3rd-generation EGFR inhibitors as well as anti-EGFR antibodies, neither of which can maintain or regress tumor volume in the presence of resistance as monotherapies. CCM Biosciences is advancing clinical candidates from its EGFR inhibitor program to investigational new drug (IND) filing this year for entry to clinical trials. The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 -- -- and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them. About CCM Biosciences CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue, enabling fully integrated drug discovery and development. View source version on Contacts Anisha Ghosh anisha@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
Company's NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J., May 20, 2025--(BUSINESS WIRE)--CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world's top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop resistance mutations including the T790M gatekeeper mutation. Osimertinib, a 3rd-generation covalent TKI, is efficacious against the T790M resistance mutation and prevents its onset if administered as first line therapy. However, treatment with Osimertinib inevitably induces additional mutations, especially the C797S mutation, as well as various off-target resistance mechanisms. To date, there are no approved therapies capable of overcoming mutational or non-mutational resistance to 3rd-generation TKIs. As such, there is an urgent unmet medical need to develop next-generation EGFR inhibitors that overcome these forms of resistance. While billions of dollars have been invested over the last several years on the development of 4th-generation EGFR inhibitors that overcome tumor resistance to 3rd-generation inhibitors, due to the diversity of resistance mechanisms, these inhibitors have failed to progress beyond early-stage clinical trials. At ASCO 2025, CCM Biosciences' presentation "Novel, potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy" in the Lung Cancer – Non-small cell – Metastatic session (Abstract #: 8622, will report novel 4th-generation, orally bioavailable EGFR inhibitors (CCM-205, CCM-245 and CCM-308) that can overcome both on-target and off-target resistance in lung cancer models, significantly outperforming the aforementioned 4th-generation inhibitors in the face of resistance to 3rd-generation inhibitors, and have significant potential clinical applications. In addition to their potent activity as monotherapies, CCM-205 and CCM-245 are highly efficacious in combination with 3rd-generation EGFR inhibitors as well as anti-EGFR antibodies, neither of which can maintain or regress tumor volume in the presence of resistance as monotherapies. CCM Biosciences is advancing clinical candidates from its EGFR inhibitor program to investigational new drug (IND) filing this year for entry to clinical trials. The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 -- -- and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them. About CCM Biosciences CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue, enabling fully integrated drug discovery and development. View source version on Contacts Anisha Ghosh anisha@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Al Etihad
31-03-2025
- Business
- Al Etihad
UAE set to host major global events in April
ABU DHABI (WAM)The United Arab Emirates is set to host a wide range of major conferences, exhibitions, and global events throughout April, reflecting its influential role in shaping the future of several vital sectors regionally and events hosted in the UAE are distinguished by broad international participation, further strengthening its position as the world's leading destination for business tourism and international conferences. AIM Congress 2025 Emergency and Crisis Management 2025The National Emergency Crisis and Disasters Management Authority is organising the 8th edition of the World Crisis & Emergency Management Summit 2025, which will take place from 8th to 9th April at ADNEC Abu Dhabi. The authority also announced the organisation of the "Crisis Management Technologies Exhibition" to run in parallel with the summit, aiming to showcase the UAE's leadership in fostering global partnerships, innovation, and the use of advanced technologies, with a focus on joint strategic initiatives that support preparedness and effective crisis response. Air Traffic ManagementAbu Dhabi will host the 64th edition of the Annual Conference of the International Federation of Air Traffic Controllers' Associations (IFATCA 2025) from 28th April to 2nd May, with extensive participation from international organisations, government agencies, and many leading companies in the civil aviation sector. Local ProductionThe 3rd edition of the World Local Production Forum will be held from 7th to 9th April at ADNEC, attracting over 4,000 participants. The forum will discuss key issues related to sustainable local production, technology transfer, and ways to enhance partnerships to ensure fair access to high-quality health products. Abu Dhabi Global Healthcare WeekThe Department of Health – Abu Dhabi is preparing to launch the second edition of Abu Dhabi Global Healthcare Week, taking place from 15th to 17th April 2025 at ADNEC. The event is expected to attract over 15,000 participants and more than 325 exhibiting entities. Culture Summit Abu DhabiThe Department of Culture and Tourism – Abu Dhabi is organising the 7th edition of its leading global platform, the Culture Summit Abu Dhabi, to be held from 27th to 29th April 2025 at Manarat Al Saadiyat in Abu Dhabi's cultural district. The summit will be held under the theme "Culture for Humanity and Beyond", and will spotlight the vital relationship between culture and humanity in a time of accelerated transformation. Global Justice, Love & Peace Summit AI WeekDubai AI Week will take place from 21st to 25th April 2025, featuring numerous conferences, initiatives, and exhibitions that reflect Dubai's vision for the future of AI and its vast opportunities. The event will host the third edition of the "Machines Can See" Summit and the Dubai AI Festival, which is expected to attract over 8,000 AI experts, more than 500 investors, and over 100 speakers and 100 exhibitors from more than 100 countries. Gaming and EsportsThe Dubai Festivals and Retail Establishment has announced the launch of the 4th edition of the Dubai Esports and Games Festival, the largest event of its kind in the region, taking place from 25th April to 11th May 2025. The festival will feature GameExpo, the GameExpo Summit, the Dubai Cosplay Championship, Play Beyond competitions, along with city-wide tournaments, educational challenges, and interactive experiences that allow visitors to explore and learn within the gaming world. Arabian Travel MarketThe next edition of the Arabian Travel Market (ATM) will be held at the Dubai World Trade Centre from 28th April to 1st May 2025. The event is expected to attract over 47,000 participants and will feature more than 2,600 exhibitors representing over 161 global destinations. Sharjah Children's Reading FestivalThe 16th edition of the Sharjah Children's Reading Festival will be held from 23rd April to 4th May 2025 at Expo Centre Sharjah. The festival will present a wide range of new book releases for children and youth, alongside a rich programme of interactive activities, theatrical and artistic performances, and educational and entertainment events lasting 12 days.
